The Cheapest Tube in the Room: Rethinking Diagnostic Value Beyond Unit Price

A diagnostic test can look inexpensive on a procurement spreadsheet and still be the most expensive option in the system. The unit price captures what arrives in the box. It does not capture what happens when the result is ambiguous, delayed, repeated, disputed or never acted upon. In UK primary care and community diagnostics, where appointment capacity is scarce and follow-up work is often invisible, that distinction matters. The cheapest tube in the room is not necessarily the cheapest pathway.

The invoice is not the cost

Commissioners are rightly attentive to price. But a test’s value is not its sticker cost. It is the cost of obtaining a clinically useful answer and acting on it within an acceptable time. A low-cost assay that generates a high proportion of indeterminate results may trigger repeat sampling, additional appointments, patient calls and clinician uncertainty. A more expensive test that resolves the question in one step may reduce the total burden on the NHS.

This is not an argument for buying the most sophisticated test available. It is an argument for counting the whole pathway. The relevant question is not “What does the test cost?” but “What does it cost to get a result that changes management, and what happens to the patients who do not get one?”

A practical total-pathway model

A workable model for local teams is to calculate total-pathway cost per clinically actionable result. That means adding the visible and hidden components of the pathway, then dividing by the number of results that genuinely inform care. The components typically include:

• Acquisition and consumables: the test itself, collection materials, reagents, controls and calibration.
• Staff time: sample collection, preparation, running the test, quality control, interpretation and recording.
• Training and competency: initial training, refresher training, audit and supervision.
• Governance and quality assurance: accreditation activity, incident review, audit and equipment maintenance.
• Transport and logistics: moving samples or devices, storage conditions and chain of custody.
• Confirmatory testing: the proportion of results that require a second, more definitive test.
• Follow-up and administration: recalling patients, explaining results, arranging repeat tests and updating records.
• Downstream consequences: unnecessary referrals, additional investigations or delayed decisions caused by an unclear result.
• Patient burden: time off work, travel, anxiety and the cost of repeated attendance.

Not every item is easy to quantify. That is not a reason to ignore it. A simple local model with explicit assumptions is more useful than a unit-price comparison that pretends the rest of the pathway does not exist.

Everyday examples from UK care

Consider a point-of-care test used in general practice to rule a condition in or out before referral. If the test is cheap but frequently indeterminate, the practice may repeat it, telephone the patient, book another appointment and ultimately refer anyway. The unit price was low; the pathway cost was not. A more specific test, used in the right patients, might cost more per cartridge but reduce repeat consultations and speed a decision.

Or consider a community diagnostic centre comparing two routes to the same clinical question. One route uses a low-cost initial test with a high false-positive rate, generating confirmatory scans and anxious conversations. The other uses a higher-cost test with better specificity, reducing the number of patients who need further investigation. The second option may be better value even if its unit price is higher, because it produces fewer dead ends.

Primary care also carries an administrative load that rarely appears in business cases. Chasing results, explaining inconclusive findings and arranging repeats consumes reception, nursing and GP time. In a system under pressure, that is not a rounding error. It is capacity that cannot be used for something else.

When a higher-cost test is the better buy

A higher-cost test is likely to be better value when it resolves uncertainty, reduces repeat testing, shortens time to decision, avoids unnecessary referrals or improves the proportion of patients who receive a clear management plan. It may also be better value when it is easier to use correctly, has fewer quality-control failures or integrates more cleanly with electronic records.

The opposite is also true. An expensive test used in the wrong population can be wasteful. A highly sensitive test in a low-prevalence setting may generate false positives and downstream anxiety. The argument is not that price should be ignored. It is that price should be assessed alongside clinical utility, operational fit and the cost of the next step.

What commissioners should ask

Commissioners and clinical teams can make better decisions by asking suppliers and pathway leads a consistent set of questions. What proportion of results are actionable? What proportion require confirmation? What is the local failure rate? How much staff time does the test consume? What happens when the result is ambiguous? How are results communicated to patients? What is the expected downstream referral rate? These questions turn a procurement decision into a pathway decision.

It is also worth modelling the cost of the status quo. A new test may look expensive against the current unit price, but the current pathway may already be carrying repeat appointments, delayed diagnoses and administrative chasing. The comparison should be like for like, not a new pathway against an old invoice.

The value of a clear answer

In 2026, the NHS is being asked to deliver more diagnostics in community settings, often with constrained budgets. That makes the total-pathway approach more important, not less. Cheap tests have a place. They can be excellent tools when they are well targeted, well governed and well understood. But cheapness is a property of the test, not of the pathway.

The most economical diagnostic is not always the one with the lowest unit price. It is the one that gives the right patient a clear answer at the right point in care, without generating a trail of repeats, referrals and reassurance calls behind it. Commissioners should count that whole trail. Clinical teams should describe it. And procurement should stop treating the invoice as if it were the bill.